Skip to main content
Molecular & Cellular Proteomics

Main menu

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us

Submit

  • Submit
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Molecular & Cellular Proteomics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us
  • Submit
Research

Identification of Cellular Proteome Modifications in Response to West Nile Virus Infection

Boris Pastorino, Elodie Boucomont-Chapeaublanc, Christophe N. Peyrefitte, Maya Belghazi, Thierry Fusaï, Christophe Rogier, Hugues J. Tolou and Lionel Almeras
Molecular & Cellular Proteomics July 1, 2009, First published on April 24, 2009, 8 (7) 1623-1637; https://doi.org/10.1074/mcp.M800565-MCP200
Boris Pastorino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elodie Boucomont-Chapeaublanc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe N. Peyrefitte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya Belghazi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Fusaï
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Rogier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugues J. Tolou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lionel Almeras
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: almerasl@imtssa.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Flaviviruses are positive-stranded RNA viruses that are a public health problem because of their widespread distribution and their ability to cause a variety of diseases in humans. West Nile virus is a mosquito-borne member of this genus and is the etiologic agent of West Nile encephalitis. Clinical manifestations of West Nile virus infection are diverse, and their pathogenic mechanisms depend on complex virus-cell interactions. In the present work, we used proteomics technology to analyze early Vero cell response to West Nile infection. The differential proteomes were resolved 24 h postinfection using two-dimensional DIGE followed by mass spectrometry identification. Quantitative analysis (at least 2-fold quantitative alteration, p < 0.05) revealed 127 differentially expressed proteins with 68 up-regulated proteins and 59 down-regulated proteins of which 93 were successfully identified. The implication for mammalian cellular responses to this neurotropic flavivirus infection was analyzed and made possible more comprehensive characterization of the virus-host interactions involved in pathogenesis. The present study thus provides large scale protein-related information that should be useful for understanding how the host metabolism is modified by West Nile infection and for identifying new potential targets for antiviral therapy.

West Nile virus (WNV)1 is a mosquito-borne flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex. The virus is maintained in nature in enzootic cycles in which it is transmitted between ornithophilic mosquitoes and avian hosts. In mammals, including humans, WNV is an encephalitic flavivirus and can cause natural infections of the central nervous system (CNS) with a neuropathogenesis involving neuroinvasiveness (ability to enter the CNS) and neurovirulence (replication within the CNS) (1). To date, no pharmacological treatment exists for WNV, and a vaccine is only available for horses.

First isolated in 1937, WNV has become endemic in Africa, the Middle East, and parts of Asia and Europe (2, 3). Phylogenetics analysis groups WNV strains into two distinct lineages. Viruses in lineage 2 are found only in Africa, whereas viruses in lineage 1 are present both in Africa and in other areas, particularly Asia and Europe. Since 1999, WNV from lineage 1 (NY99) has reached North America where, in 2002, it caused the largest arboviral meningoencephalitis outbreak ever recorded in this area (4).

It is known that flavivirus replication can cause extensive rearrangement of host cell cytoskeletal and membrane compartments leading to a “cytopathic effect” in various cell cultures of human, primate, rodent, and insect origin (5). Recent studies have revealed specific effects of viruses on cellular processes. It has been demonstrated that flaviviruses can induce cell death directly through viral replication and the production of proapoptotic proteins (6–11), but the mechanism of pathogenesis has not been elucidated.

Although neurons are regarded as the major target of WNV in vivo (2), WNV infection has been shown to induce apoptosis in different cell lines in a similar manner in vitro (12, 13). This includes a wide range of different cell types with, in particular, the African green monkey kidney continuous cell line (Vero) recommended by the World Health Organization Collaborating Center for systematic research and isolation of arboviruses as well as a substrate to develop live attenuated and inactivated vaccines. Acute infection of Vero cells by WNV produces a lytic infection with a characteristic rounding cytopathic effect and the production of a large number of infectious particles in the culture fluid within 3 days postinfection (14). Although this permissive mammalian cell system is widely used for flavivirus isolation, propagation, and titration, to date no studies have focused on identifying Vero cellular proteins whose expression has been altered by WNV infection. We considered that Vero cells could be a good model for in vitro identification of cell protein alterations with possible implication in certain pathogenic mechanisms.

In the present work, fluorescent 2D DIGE technology combined with MS analysis was used to examine the consequences of Vero cell infection by WNV. To evaluate early mammalian cell response after infection and to avoid the effect of cell death and protein degradation, the culture conditions (e.g. infectious dose and incubation time) were optimized. A total of 93 differentially expressed protein spots were identified (over ±2-fold, p < 0.05) and confirmed by fluorescent Western blot analysis. The implication for cellular responses to this flavivirus infection as well as the potential roles of certain altered identified proteins are discussed to characterize the pathophysiologic processes. This study can also provide useful clues for antiviral research.

EXPERIMENTAL PROCEDURES

Reagents

N-Hydroxysuccinimide esters Cy2, Cy3, and Cy5; urea; glycerol; mineral oil; Immobiline DryStrip gels (18 cm, pH 4–7 and 6–11); and IPG buffer solutions (pH 4–7 and 6–11) were purchased from GE Healthcare. Acrylamide, DTT, Tris, glycine, SDS, and SYPRO Ruby gel stain solution were purchased from Bio-Rad. Dimethylformamide, CHAPS, l-lysine, ammonium persulfate, iodoacetamide, agarose, bromphenol blue, and TFA were purchased from Aldrich. Thiourea, TEMED, acetone, ACN, and ethanol were purchased from Fluka (Buchs, Switzerland). Trypsin (sequencing grade) was purchased from Promega (Madison, WI). All buffers were prepared with Milli-Q water (Millipore, Bedford, MA).

Virus Production and Titration

All work with infectious virus was carried out in a biosafety level 3 laboratory. WNV strain New York 99 was provided by X. de Lamballerie (Unité des virus émergents, Faculté de médecine de la Timone, Marseille, France). The batches of viral inoculum used in this study were prepared by two passages in C6/36 cells (from Aedes albopictus; ATCC clone CRL 1660) as described previously (15). Finally cell culture supernatants were collected and frozen at −80 °C in 50 mm Hepes. Viral titers were estimated by plaque assay on Vero cells (ATTC clone CCL 81) according to the dilution method reported previously (16) and a maximum likelihood-based estimating method (17).

Infection of Vero Cells

Briefly Vero cells (ATTC clone CCL 81) were cultured in commercial Medium 199 (BioWhittaker) supplemented with 5% fetal calf serum. One day after seeding, when cultures had reached confluency, cells were infected at a multiplicity of infection (m.o.i.) of 1 for 1.5 h at 37 °C in a 5% CO2 atmosphere. Finally fresh Medium 199 was added to all wells, and the cultures were incubated at 37 °C. Twenty-four hours after virus infection, the supernatants and cells were harvested and analyzed. Mock Vero cells served as the controls and were cultured in parallel to WNV-infected cells.

Viral RNA Extraction and Real Time RT-PCR Quantification

Cell culture supernatants were collected, and viral RNA was extracted using the High Pure Viral RNA kit (Roche Diagnostics) following the manufacturer's protocol. RT-PCRs were performed on a Lightcycler thermocycler (Roche Diagnostics) using the Superscript III Platinum One-Step qRT-PCR kit (Invitrogen) as described previously (18). Specific WNV TaqMan® probes and primers used were synthesized (Eurogentec S.A., Herstal, France) in accordance with published detection assays (19).

Indirect Immunofluorescence Assay

Vero cells were grown in an eight-microchamber Lab-Tek slide (Nunc, Roskilde, Denmark) for 24 h. Cells were then either infected at an m.o.i. of 1 with WNV or left untreated. Twenty-four hours after virus infection, supernatants were collected for virus titration, and cells were fixed with 3% paraformaldehyde in PBS. Viral antigens in infected cells were detected by indirect immunofluorescence assay using WNV-specific hyperimmune mouse ascitic fluids (1:100) and Alexa Fluor 488-conjugated goat anti-mouse IgG (1:100) (Molecular Probes) (20). A DAPI counterstaining was performed to visualize cell nuclei, and the percentage of positive cells was determined using a fluorescence microscope (Zeiss Axioskop 40).

Detection of Apoptosis

Vero cells were grown in an eight-microchamber Lab-Tek slide (Nunc) and infected as described above. Twenty-four and 36 h after infection, WNV-infected cells and mock controls were fixed with 3% paraformaldehyde in PBS. After a DAPI counterstaining, apoptosis was detected by means of TUNEL analysis with fluorescein-dUTP (In Situ Cell Death Detection kit, Roche Diagnostics). Infected and mock cells were then counted under a fluorescence microscope (Zeiss Axioskop 40).

Protein Sample Preparation

Twenty-four hours after WNV infection, infected and mock cells were lysed using standard cell lysis buffer containing 8 m urea, 2 m thiourea, 4% (w/v) CHAPS, and 30 mm Tris, adjusted to pH 8.5. The cells were disrupted by ultrasonication (Vibracell 72412, Bioblock Scientific, Illkirch, France) five times for 60 s on ice at maximum amplitude. The resulting homogenate was centrifuged for 15 min at 16,000 × g at 4 °C, and the supernatant was further precipitated with 100% acetone. Protein concentrations for each sample were determined in duplicate using the Lowry method (DC Protein Assay kit, Bio-Rad) according to the manufacturer's instructions and confirmed by SDS-PAGE. Samples were resuspended in standard cell lysis buffer to obtain a protein concentration adjusted to 2.5 μg/μl.

CyDye Labeling

Proteins in each sample were minimally labeled with CyDye according to the manufacturer's recommended protocols. In short, 50 μg of each protein sample were labeled with 400 pmol of either Cy3, Cy5, or Cy2 (Cy2 was used to label the internal standard) freshly dissolved in anhydrous dimethylformamide and incubated on ice for 30 min in the dark. The reaction was quenched with 1 μl of free lysine (10 nm) by incubation for 10 min on ice. Cy3-, Cy5-, and Cy2-labeled samples were then pooled, and an equal volume of 2× sample buffer was added (8 m urea, 2 m thiourea, 4% (w/v) CHAPS, 10 mm DTT, and 1.2% (v/v) IPG buffer corresponding to the IPG strips used).

Isoelectric Focusing

DeStreak buffer containing 1.2% (v/v) IPG buffer (pH 4–7 or 6–11) was used for overnight rehydration of 18-cm IPG strips with different pH gradient ranges (4–7 or 6–11). The samples were applied at the acidic end of the IPG strips using a cup-loading technique. IEF was carried out at 20 °C for a total of 65 kV-h on an Ettan IPGphor II electrophoresis unit (GE Healthcare).

Second Dimension Electrophoresis

Prior to separation in the second dimension, the IPG strips were reduced and alkylated in equilibration buffer containing 50 mm Tris-HCl, pH 8.6 buffer, 6 m urea, 2% SDS, and 30% glycerol supplemented with 1% (w/v) DTT or 2.5% (w/v) iodoacetamide instead of DTT for 15 min. Equilibrated IPG strips were then transferred onto 10% uniform polyacrylamide gels cast in low fluorescence glass plates using an Ettan-DALT Six system (GE Healthcare). Strips were overlaid with 0.5% agarose in 1× running buffer containing bromphenol blue, and electrophoresis was run at 10 watts/gel until the dye front migrated out of the gel at 20 °C.

Image Analysis

After electrophoresis, the gels with CyDye-labeled proteins were scanned three times with a TyphoonTM Trio image scanner (GE Healthcare) each time at different excitation wavelengths (Cy3, 580 BP 30/green (532 nm); Cy5, 670 BP 30/red (633 nm); Cy2, 520 BP 40/blue (488 nm)). Prescans were performed to adjust the photomultiplier tube voltage to obtain images with a maximum intensity of 60,000–80,000 U. Images were cropped with ImageQuantTM software (GE Healthcare) and further analyzed using the software package DeCyder v6.5 (GE Healthcare). Intragel spot detection and quantification were performed using the differential in-gel analysis mode, whereas images from different gels were matched using the biological variance analysis mode. Matching between gels was performed using the in-gel standard from each image pair. The paired t test was used for statistical analysis of the data. A false discovery rate (FDR) correction was applied to eliminate false positives. Protein spots that were expressed differentially between two experimental groups (|ratio| ≥ 2, p ≤ 0.05) were marked. After 2D DIGE imaging and image analysis, the protein spot pattern was visualized by SYPRO Ruby staining (Bio-Rad) according to the manufacturer's protocol.

In-gel Digestion

Based on the DeCyder v6.5 analysis, spots of interest were excised using a manual spot picker from SYPRO Ruby stain gels. Excised plugs were digested overnight at 37 °C by sequencing grade trypsin (12.5 μg/ml; Promega) in 50 mm NH4HCO3. The resulting extracted peptides were then stored at −20 °C before their analysis by MS.

Mass Spectrometry Analysis

The samples were analyzed by nanoscale capillary LC-MS/MS. Purification and analysis were performed on a C18 capillary column using a CapLC system (Waters, Milford, MA) coupled to a hybrid quadrupole orthogonal acceleration time-of-flight tandem mass spectrometer (Q-TOF Ultima, Waters). Chromatographic separations were conducted on a reversed-phased capillary column (AtlantisTM dC18, 3 μm, 75 μm × 150 mm; Nano EaseTM, Waters) with a 180–200 nl min−1 flow. The gradient profile consisted of a linear gradient from 95% A (H2O, 0.1% HCOOH) to 60% B (80% acetonitrile, 0.1% HCOOH) in 60 min followed by a linear gradient to 95% B in 10 min. Mass data acquisitions were piloted by MassLynx 4.0 software using automatic switching between MS and MS/MS modes. The internal parameters of Q-TOF were set as follows. The electrospray capillary voltage was set to 3.2 kV, the cone voltage was set to 30V, and the source temperature was set to 80 °C. The MS survey scan was m/z 400–1300 with a scan time of 1 s and an interscan time of 0.1 s. When the intensity of a peak rose above a threshold of 15 counts, tandem mass spectra were acquired. Normalized collision energies for peptide fragmentation were set using the charge state recognition files for +2 and +3 peptide ions. The scan range for MS/MS acquisition was from m/z 50 to 1500 with a scan time of 1 s and an interscan time of 0.1 s. Fragmentation was performed using argon as the collision gas and with the collision energy profile optimized for various mass ranges and charges of precursor ions. Mass data collected during a nanoscale capillary LC-MS/MS analysis were processed using ProteinLynx Global Server 2.2 software (Waters) with the following parameters: no background substraction, smooth 3/2 Savitzky Golay, and no deisotoping to generate peak lists in the Micromass pkl format. pkl files were then fed into a local search engine, Mascot Daemon v2.2.2 (Matrix Science, London, UK). The data were searched against the primates (295,078 sequences) and viruses (435,150 sequences) National Center for Biotechnology Information non-redundant (NCBInr) protein database (December 2, 2007). Search parameters allowed for one missed tryptic cleavage site, the carbamidomethylation of cysteine, and the possible oxidation of methionine; precursor and product ion mass error tolerance was <0.2 Da. All identified proteins have a Mascot score greater than 69, corresponding to a statistically significant (p < 0.05) confident identification. Moreover among the positive matches, only protein identifications based on at least two different non-overlapping peptide sequences of more than 6 amino acids and with a mass tolerance <0.05 Da were accepted. These additional validation criteria are a good compromise to limit the number of false positive matches without missing real proteins of interest.

SDS-PAGE, Blotting, and Analysis Procedures

Immunoblotting with fluorescence-based methods including the ECL Plex-CyDye immunoblot detection system (GE Healthcare) was used to detect both the total protein expression profile and the specific immunoreactive proteins. The same protein samples used for 2D DIGE were minimally labeled with Cy3 cyanine dye as described above (see “CyDye Labeling”). Labeled samples were separated by 10% SDS-PAGE in a Mini-PROTEAN Cell (Bio-Rad) according to Laemmli (21). Gels were transferred to a nitrocellulose membrane (0.45 μm; GE Healthcare) using a semidry blotting system at 200 mA for 30 min (22). Blots were saturated with 5% nonfat dried milk in PBS containing 0.1% (v/v) Tween 20 for 1 h. Western blot analyses were carried out with anti-tubulin (1:500, mouse IgG isotype FITC conjugate) (clone DM1A, Sigma), anti-vimentin (1:500, mouse IgG isotype) (clone V9, Sigma), anti-enolase (1:1000, rabbit antibody) (Sigma), and anti-transglutaminase type 2 (1:2000, goat antibody) (Sigma) diluted in PBS containing 0.2% (v/v) Tween 20 with 5% nonfat dried milk. After 2 h of incubation at room temperature, anti-vimentin and anti-enolase were revealed with ECL Plex goat anti-mouse IgG Cy2- and goat anti-rabbit IgG Cy5-conjugated secondary antibody (GE Healthcare) (1:2000), respectively. Anti-transglutaminase was revealed with mouse anti-goat IgG FITC conjugate (1:2000) (Jackson ImmunoResearch Laboratories, West Grove, PA). All manipulations were protected from light. The gels, just after the electrophoresis and immunoblots, were scanned using a Typhoon Trio image scanner as described above (see “Image Analysis”). Immunoreactive bands were analyzed using Quantity One software (Bio-Rad). To evaluate the expression level of the different proteins, immunoreactive band intensities were normalized to the intensities of a global protein pattern labeled with Cy3. Band intensities were also corrected for adjacent background. Standard molecular weight markers were loaded in each gel (Bio-Rad).

RESULTS

Virus Infection Conditions

Optimal culture conditions (e.g. infectious dose and incubation time) were tested to determine the early host responses of Vero cells following WNV infection at the proteome level. Chu and Ng (12) have previously studied the effect of WNV infectious dose on the process of cell death. The authors demonstrated that a low infectious dose of virus (m.o.i. ≤ 1) induced a delay in the kinetics of virus replication and in apoptotic cell death in Vero cells. To obtain a high percentage of infected cells with minimal cell death in our assays, a m.o.i. of 1 and 24 h postinfection were the conditions chosen for subsequent proteomics analysis. Under these conditions, more than 90% of cells were infected by the virus, and cell death was less than 2%, comparable to the mock control cells. DNA fragmentation by TUNEL assay was controlled with mock- and WNV-infected Vero cells cultivated for 36 h with a m.o.i. of 1. In these conditions, up to 10% of infected cells were labeled with fluorescein-dUTP. A representative result of three independent experiments is shown in Fig. 1. Moreover real time RT-PCR quantification of WNV RNA in the cell culture supernatants indicated a productive virus infection (data not shown).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Evaluation of virus infection and cell viability. Mock- (a, c, and e) or WNV-infected (b, d, and f) Vero cells at 24 (a, b, c, and d) or 36 h (e and f) postinfection were observed under a fluorescence microscope. a and b, viral antigens (green) were detected by immunofluorescence assay using WNV-specific hyperimmune mouse ascitic fluids (1:100) and Alexa Fluor 488-conjugated goat anti-mouse IgG (1:100). c, d, e, and f, apoptosis (green) was revealed by the incorporation of fluorescein-dUTP at the free 3′-hydroxyl ends of fragmented DNA by TUNEL staining assay. A DAPI counterstaining was performed to visualize cell nuclei (blue).

Analysis of Differentially Expressed Proteins after WNV Infections

To identify the cell proteins involved in response to WNV infection, 2D DIGE experiments were performed. Four independent cultures of mock- and WNV-infected Vero cells cultivated for 24 h with a m.o.i. of 1 were included in this analysis. After 2D DIGE, the Cy2, Cy3, and Cy5 channels of each gel were individually imaged, and the images were analyzed using DeCyder 6.5 software.

For proteins separated in the pH 4–7 range, 1950 protein spots were matched. Of them, 79 spots were significantly modified between the mock- and WNV-infected Vero cells (33 spots were up-regulated, and 46 spots were down-regulated; |ratioWNV/mock| ≥ 2, p ≤ 0.05 after FDR correction; spots shown in Fig. 2). For proteins separated in the pH 6–11 range, 1674 protein spots were matched. Of them, 48 spots were significantly modified between the mock- and WNV-infected Vero cells (35 spots were up-regulated, and 13 spots were down-regulated; |ratioWNV/mock| ≥ 2, p ≤ 0.05 after FDR correction; spots shown in Fig. 3). A total of 127 protein spots were found to have been modified following Vero cell infection by WNV under our conditions.

Fig.2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.2.

2D DIGE analysis of mock- or WNV-infected Vero cells at 24 h postinfection (m.o.i. = 1). Representative data from a 2D DIGE experiment using a 10% homogenous SDS-polyacrylamide gel with the pH range from 4 to 7 is shown. Proteins from mock-infected Vero cells were conjugated to Cy5, and proteins from WNV-infected Vero cells were conjugated to Cy3. As determined by DeCyder software, protein spots that were differentially expressed between two experimental conditions (|ratio| ≥ 2, p ≤ 0.05 after an FDR correction) were marked with master numbers. Normal and italic numbers correspond to protein spots significantly up- and down-regulated following Vero cell infection by WNV, respectively. Proteins identified by mass spectrometer are listed in Table I.

Fig.3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.3.

2D-DIGE analysis of mock- or WNV-infected Vero cells at 24 h postinfection (m.o.i. = 1). A, representative data from a 2D DIGE experiment using a 10% homogenous SDS-polyacrylamide gel with the pH range from 6 to 11 is shown. Proteins from mock-infected Vero cells were conjugated to Cy3, and proteins from WNV-infected Vero cells were conjugated to Cy5. As determined by DeCyder software, protein spots that were differentially expressed between two experimental conditions (|ratio| ≥ 2, p ≤ 0.05 after an FDR correction) were marked with master numbers. Normal and italic numbers correspond, respectively, to protein spots up- and down-expressed following Vero cell infection by WNV. Numbers correspond to proteins identified by mass spectrometer in Table II. B, enlarged area of the gel; spots differentially expressed between mock- and WNV-infected cells are noted.

Identification of Differentially Expressed Proteins after WNV Infection

One hundred and twenty-seven differentially detected protein spots were excised manually from gels, subjected to in-gel digestion, and analyzed by LC-MS/MS. The resulting fragment ion spectra were searched against primate and viral protein databases (NCBInr). Tables I and II list proteins that were identified by tandem mass spectrometry from gels with pH ranges of pH 4–7 and pH 6–11, respectively. Ninety-three protein spots (73%) were identified with a high degree of confidence (Tables I and II and supplemental Tables 1 and 2). As expected, 15 protein spots with a significant average ratio -fold change were identified as WNV proteins such as polyprotein precursor or nonstructural protein 1 (NS1), NS3, and NS5 (Tables I and II).

View this table:
  • View inline
  • View popup
Table I Proteins identified from the differential 2D DIGE (pH 4–7) analysis after WNV infection

The proteins were identified by mass spectrometry following in-gel trypsin digestion. The spot numbers correspond to the same numbers as indicated on Fig. 2. The identities of the spots, their NCBI accession numbers, and the theoretical molecular masses and pI values as well as the number of peptide sequences, the corresponding percent sequence coverage, and the Mascot score are listed for MS/MS analysis. (Protein scores greater than 69 are considered as significant (p < 0.05).) Paired average volume ratio and p values (ttest) between Vero cells infected by WNV versus uninfected cells (WNV/mock) were quantified using DeCyder software. n.i., no identification; TNF, tumor necrosis factor; CTBP, C-terminal-binding protein; CBP, cAMP-response element-binding protein.

View this table:
  • View inline
  • View popup
Table II Proteins identified from the differential 2D DIGE (pH 6–11) analysis after WNV infection

The proteins were identified by mass spectrometry following in-gel trypsin digestion. The spot numbers correspond to the same numbers as indicated in Fig. 3. The identities of the spots, their NCBI accession numbers, and the theoretical molecular masses and pI values as well as the number of peptide sequences, the corresponding percent sequence coverage, and the Mascot score are listed for MS/MS analysis. (Protein scores greater than 69 are considered as significant (p < 0.05).) Paired average volume ratio and p values (t test) between Vero cells infected by WNV versus uninfected cells (WNV/mock) were quantified using DeCyder software n.i., no identification.

In addition to these viral proteins, 54 distinct cellular proteins were identified according to their NCBI number (Tables I and II). The main proteins with profile modification were localized in the cytoplasm (60.7%) and nucleus (19.6%) (Fig. 4 A). These proteins were grouped into functional categories, such as transcription and translation, cytoskeletal and cell mobility, chaperones, energy pathways, apoptosis, lipid metabolism, ubiquitin-proteasome pathway, regulation and metabolism of nucleotide, binding, and transport (Tables I and II and Fig. 4B). Several proteins (e.g. vimentin and transglutaminase 2) were detected in more than one spot, suggesting different isoforms and/or post-translational modifications. Tumor rejection antigen (gp96) protein (Table I) was detected in seven spots with an up-representation for three of them (that is 436, 437, and 442) and a down-representation for four of them (that is 1187, 1189, 1192, and 1195). These results indicated that following WNV infection of Vero cells a group of host protein isoforms (e.g. 436, 437, and 442) was privileged to the detriment of the second group of other isoforms from the same host protein. Thirty-four protein spots were not identified probably because of insufficient amounts of protein or of low MS spectra qualities.

Fig.4
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.4

Pie chart representing up- and down-regulated proteins identified by mass spectrometry following Vero cell infection by WNV. Proteins have been classified according to their subcellular location (A) and biological function (B). The percentages of proteins associated with each category are indicated in parentheses.

Protein Validation by Western Blotting Analysis

To verify the 2D DIGE results, Western blot analyses were performed. Several proteins identified by MS were selected on the basis of their representativity and the availability of the corresponding antibodies. For all Western blots, each protein sample was labeled with Cy3 cyanine dye revealing the variations in sample loading that were taken into account for the calculation of the average band volume ratio. The same samples used for 2D DIGE analysis were subjected to one-dimensional SDS-PAGE and blotted with the antibodies against tubulin, vimentin, transglutaminase, and enolase.

Anti-tubulin FITC-conjugated antibody confirmed that this protein was up-regulated following WNV infection of Vero cells (Table I and Fig. 5 ). For vimentin, the antibody detected two molecular weight isoforms (Fig. 5A). This is consistent with the results of 2D DIGE analysis that showed two groups of protein spots (1482 and 1483 and 1574, 1575, and 1577) corresponding to vimentin with different molecular weights. Both analyses indicated, for the two groups of protein spots, a down-representation of vimentin following WNV infection (Fig. 5B). Anti-transglutaminase antibodies detected two bands by Western blot that were up-regulated following WNV infection (Fig. 5, A and B). Although proteomics analysis identified two protein spots (741 and 742) corresponding to transglutaminase that were also up-expressed following WNV infection (Fig. 2 and Table I), these two protein spots were transglutaminase isoforms with the same molecular weight. These two protein spots could thus correspond to only one of the two bands detected on the Western blot. It could effectively be hypothesized that the expression level of the highest band and its -fold change detected on the Western blot were not sufficient for the inclusion of this isoform in the list of statistically significant protein spots differently regulated following WNV infection using proteomics analysis. Using anti-enolase antibodies, we confirmed the down-expression of this protein (Fig. 5). Thus, Western blot experiments confirmed the results obtained by 2D DIGE analysis and protein identification by mass spectrometry.

Fig.5
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig.5

Western blot validations of differentially expressed proteins. A, the same protein samples used for DIGE analysis were minimally labeled with Cy3 cyanine dye. At the top, a representative protein profile of the four biological replicates from lysates of mock- and WNV-infected Vero cells separated by 10% SDS-PAGE is shown. Immunoblotting with fluorescence-based methods was used to detect an overlaid fluorescent scan of the general protein patterns (Cy3 dye (green)) and the specific immunoreactive proteins (FITC/Cy2 dye (yellow) or Cy5 dye (blue)). The arrows indicate the specific protein bands revealed. Standard molecular masses are indicated on the left. MW, molecular weight; kDa, kilodalton. B, the graphs correspond to the mean ± S.D. of protein quantity measured by densitometry of antigenic bands. Densitometry analyses were done using Quantity One software (Bio-Rad), and data were normalized to levels of global protein pattern intensity. Results are mean ± S.D. of the four biological replicates, and -fold change from WNV-/mock-infected is shown at the top of each graph. A.U., arbitrary units.

DISCUSSION

A clear understanding of WNV pathogenesis is lacking, so the discovery of new virus-host interactions is necessary to identify novel strategies to treat or prevent this viral infection. Despite the importance of mosquito-borne virus diseases, few studies have examined host metabolism alterations following flavivirus infection. In this way, microarray studies have analyzed changes at the transcription level in response to dengue virus (DENV) or WNV infections (23–28). To date, only two studies have analyzed the interplay between flavivirus and host cells using proteomics analysis (31, 32), and more investigations are needed to understand the mechanism of virus replication and pathogenesis. However, studies combining transcriptomics and proteomics analysis indicated that significant divergence could be observed between protein levels and mRNA abundance (29, 30). In this way, our study provides global information on protein alterations in mammalian cells infected by WNV, an emergent pathogenic flavivirus. Of the 127 spots differentially expressed in Vero cells after WNV infection according to 2D DIGE technology, 93 protein spots were identified. The identified cellular proteins function in diverse biological processes, and some functional groups are formed through cluster and pathway analysis. The potential roles of some of these altered proteins belonging to major clusters in response to WNV infection are discussed below in relation with pathogenesis and early host antiviral response.

Alteration of Cytoskeleton Networks

The altered microtubule-associated protein identified in the present work, i.e. tubulin α, was up-regulated, whereas the intermediate filament protein vimentin was down-regulated in WNV-infected Vero cells. Like many viruses (33), flaviviruses have to manipulate and utilize the host cytoskeleton to promote viral infection, but this mechanism is still unclear.

Microtubules and microtubule-associated proteins are known to play an important role in the intracellular trafficking of viral components as wells as virions in the infected host cell (34). The actin filaments were shown to be involved in mediating the internalization of WNV particles into mammalian cells by clathrin-dependent endocytosis (35). Moreover it has been demonstrated that actin filaments also play a key role in the release of West Nile (Sarafend) virions (36). Microtubules are cytoskeleton polar structures constituting α- and β-tubulin subunits that perform general functions including organelle movement and cargo transport in all kinds of cells. A previous study has shown that JEV infection induced ultrastructural changes in Vero cells with microtubule rearrangement and redistribution (37). This phenomenon could facilitate the transport of viral proteins from the rough endoplasmic reticulum (ER) and Golgi apparatus to the convoluted membrane, which may serve as a reservoir for viral proteins during JEV multiplication. Furthermore as tubulin exhibits the functions of a chaperone (38), overexpression of its cellular component may also help viral proteins to maintain their conformation in the convoluted membrane.

Vimentin is a major component of the type III intermediate filaments found in many cell lines (39). This 57-kDa protein serves to maintain cell shape and to anchor and position the nucleus within the cell. Major changes in the distribution of vimentin are observed when cells move or divide (40, 41), but this protein is also redistributed in cells expressing misfolded proteins and during virus infection (42, 43). The vimentin rearrangements with the formation of a cage structure often observed could represent a protective response by the cell during virus infection (44). In fact, the vimentin cage may have a cytoprotective role by preventing the diffusion of viral components into the cytoplasm. Several studies have shown that human immunodeficiency virus type 1 protease cleaves the intermediate filament vimentin and induces the collapse of vimentin in infected cells (45, 46). Further elucidation is in progress to determine whether the flaviviral NS2B-NS3 protease can cleave vimentin, resulting in strongly decreased levels and the collapse of the vimentin network. On the other hand, vimentin is also implicated in the regulation of cell death via its caspase-mediated cleavage (47, 48), and the observed down-regulation of the protein could also be related to the induction of apoptosis in WNV-infected Vero cells (49).

Stress Response Proteins

The quantities of two specific cellular proteins related to oxidative stress were found to have been modified in WNV-infected Vero cells. The 70-kDa heat shock protein (Hsp70) was highly expressed, whereas Hsp90 was down-regulated. Eukaryotic Hsp70s are highly abundant cytosolic and nuclear molecular chaperones that play essential roles in various aspects of protein homeostasis (50). Moreover the antiviral activity of some drugs has been associated with the induction of the specific Hsp70 (51, 52). Additionally it has been shown that Hsp70 was able to prevent the cytotoxic effects of the WNV capsid protein, suggesting a protective cell function for this molecular chaperone against WNV infection (53). However, the specific overexpression of Hsp70 by flavivirus infection has not been described until now. Thus, the present study provides the first demonstration of the up-regulation of Hsp70 after WNV infection, highlighting the possible role of this specific chaperone as a protector of the cell from apoptosis (54).

Hsp90 is a molecular chaperone that is highly expressed in most cell types in various organisms (55). It displays ATP-dependent folding capacity (56) and appears to have a specific set of client proteins in vivo unlike its promiscuous cousin chaperone Hsp70 (57, 58). Hsp90 involvement in viral replication has been reported for many viruses, and it has been demonstrated that Hsp90 inhibition blocks viral replication (59). Several viruses require viral and host molecular chaperones for entry, replication, and assembly as well as other steps in viral production (60, 61). Recently a role for Hsp90 in the control of hepatitis C, flock house, and influenza virus polymerase function has been shown (62–65), and it has been proposed that Hsp90 is a major host factor that is of central importance for viral replication for a wide spectrum of RNA viruses (66). The chaperone Hsp90 has also been identified as an essential factor in the folding and maturation of picornavirus capsid proteins (67). The importance of Hsp90 for the replication of multiple viruses opens up an interesting possibility for developing new antiviral therapies that have not yielded drug-resistant viruses (68). Although the down-regulation of Hsp90 observed in WNV-infected Vero cells was not expected, this result may still be an innate cellular response reflecting an early cellular survival mechanism against WNV infection.

RNA Processing Machinery and Host Translation Pathway

Among the differentially expressed host proteins, many of them are known to participate in viral replication and translation (Tables I and II). Positive-strand RNA viruses must recruit normal components of host cellular RNA processing or translation machineries for viral RNA synthesis and protein synthesis (69).

Human hnRNP C1/C2 are members of the heterogeneous nuclear ribonucleoprotein family, which consists of 20 major hnRNP proteins (designated hnRNP A1 through U) with molecular sizes of ∼36–120 kDa (70). These proteins are involved in mRNA biogenesis and contain important conserved motifs essential for RNA binding, protein-protein interaction, and nuclear localization. Several ribonucleoproteins, hnRNP Q, A1, A2/B, H, and YB-1 have been found to bind specifically to DENV 3′-untranslated region, suggesting that these molecules may play a biologically significant role in the DENV life cycle (71). Moreover YB-1 is directly involved in repression of DENV translation and can participate in early innate immune responses during DENV infection. A specific association has also been demonstrated between hnRNP C1/C2 and dengue virus NS1 proteins that may be favorable for virus survival in host cells (72). In the present work, hnRNP L and hnRNP U were identified for the first time as being significantly up-regulated in Vero WNV-infected cells, suggesting that these two specific host cellular proteins play a key role in WNV replication. Interestingly we also observed a depletion of the poly(rC)-binding protein (αCP-2) after WNV infection. This protein has multiple functions in post-transcriptional control of host and viral gene expression. With regard to the hepatitis A virus, it has been demonstrated that αCP-2 is cleaved by the viral protease 3C, which could down-regulate viral protein synthesis, giving way to viral RNA synthesis (73). Because of several differences between picornavirus and flavivirus replication strategies (genome cyclization and cap-dependent translation), the role of αCP-2 in the flavivirus regulation life cycle remains to be elucidated. In this study, another important regulating protein, nucleolin, was found to be more abundant in WNV-infected cells. Nucleolin is one of the most abundant nonribosomal proteins in the nucleolus, and it shuttles between nucleoli, nucleoplasm, cytoplasm, and the cell surface (74). Previous works have reported that nucleolin plays a role in virus replication with direct interaction with the hepatitis C viral RNA-dependent RNA polymerase or overexpression in herpes simplex virus-infected cells (75, 76). Based on these data, an up-regulation of nucleolin in WNV-infected Vero cells suggests that the host protein plays an important part in flavivirus biology, making possible future drug target development.

Translation factors have been well documented as playing crucial roles in viral RNA and protein synthesis (77). Moreover it is known that flaviviruses do not shut off host protein synthesis and must compete with the cellular translation machinery for limiting factors (78). In this way, the eukaryotic translation elongation factors 1A (eEF1A) have been identified as up-regulated proteins or important host cell factors for viral RNA replication during DENV or WNV infection (32, 79). In the present study, an increase in the eEF2 level was observed in the WNV-infected Vero cells suggesting that this protein may also play an important role in the translation of WNV viral RNA. Additionally several tRNA synthetases (glutamyl-prolyl/glutaminyl/tryptophanyl-tRNA synthetases) were shown to be overexpressed during WNV infection, suggesting that their overall up-regulation is required for virus propagation in Vero cells. Because flaviviruses prevent the shutoff of host cell translation, the decrease in the eukaryotic translation initiation factor 3 (eIF3) was not expected in WNV-infected Vero cells. eIF3 is one of the 11 or more initiation factors that are involved in the first stage of protein synthesis in eukaryotes. This initiation factor plays an important role by bridging the 43 S preinitiation complex to mRNA via the cap-binding complex eIF4F (80). In coronavirus-infected cells, no obvious inhibition of host protein synthesis was observed at least at early stages of the virus infection cycle. However, eIF3f has been identified as a regulator of the translation of virus-induced genes at late stages of the virus infection cycle (81). Although proteases of many picornaviruses and caliciviruses are known to cleave several translation factors (82, 83), this phenomenon had not yet been reported during flavivirus infection. Thus, the eIF3 down-expression observed in WNV-infected Vero cells may be the reflection of translation regulation mechanisms exploited by flavivirus as a means of controlling viral pathogenesis that have not been described yet.

Apoptotic Pathways

Apoptosis has opposing effects on viral pathogenesis by either preventing viral dissemination or promoting viral spread by release of the progeny virus. However, in the case of neurotropic viruses such WNV, neuron cell death has serious consequences for the host, and elucidation of virus-triggered apoptotic pathways may be critical for the understanding of the pathogenicity of flavivirus (49).

The programmed cell death 8 protein or apoptosis-inducing factor (PDCD8/AIF) is a flavoprotein localized in the mitochondrial intermembrane space, and its translocation to the nucleus induces chromosome condensation and fragmentation (84). Up-regulation of this protein in WNV-infected Vero cells reflects the induction of virus-mediated apoptosis.

Flavivirus replication is associated with extensive proliferation of intracellular membranes, which are, in part, derived from the ER. Translation of the flavivirus polyproteins is associated with the ER membranes, and the ER is also the site of viral encapsidation and envelopment. Therefore, it is likely that flavivirus infection triggers not only perturbation of ER homeostasis but also the unfolded protein response as evidenced by substantial induction of the expression of several chaperones (11). During ER stress, tumor rejection antigen, also known as gp96, is one of the important molecular chaperones that has been involved in unfolded protein response and apoptosis (85, 86). In our study, we observed a decrease in protein levels of gp96 in WNV-infected Vero cells. As already described for JEV infection (87), this phenomenon accelerates ER stress-induced apoptosis and may represent a host defense mechanism to limit viral replication.

Conclusion

Several Vero cell proteins that were modulated early in WNV infection were identified in the present study. To our knowledge, this work made it possible to identify the largest number of cellular proteins regulated differently in response to a flavivirus infection. Most of these proteins were involved in transcription/translation processes, alteration of the cytoskeleton networks, stress cellular response, and apoptotic pathways. Although the roles of some of these alterations could be related to cellular antiviral response or pathogenic mechanisms, functional significance of other altered proteins remains unclear and needs further investigation. However, the present study provides large scale protein-related information that should be useful for understanding the modulation of host metabolism in West Nile infection and for identifying new potential targets for antiviral therapy.

Acknowledgments

We thank Matthieu Pophillat and Samuel Granjeaud for technical assistance on database searching. This manuscript was reviewed and corrected by K. Snaith (Médicis Traduction), member of the French Society of Translators.

Footnotes

  • ↵* This work was supported by the French Armed Forces Medical Service and the Délégation Générale pour l'Armement (Vi-Ve-Pro-Guyane Grants 06CO006 and 05CO008-05).

  • ↵Embedded Image The on-line version of this article (available at http://www.mcponline.org) contains supplemental

  • ↵The abbrevations used are:

    WNV
    West Nile Virus
    2D
    two-dimensional
    CNS
    central nervous system
    DENV
    dengue virus
    ER
    endoplasmic reticulum
    FDR
    false discovery rate
    JEV
    Japanese encephalitis virus
    m.o.i.
    multiplicity of infection
    TEMED
    N,N,N′,N′-tetramethylethylenediamine
    DAPI
    4′ 6-diamidino-2-phenylindole
    TUNEL
    terminal deoxynucleotidyltransferase dUTP nick-end labeling
    BP
    band pass
    NCBInr
    National Center for Biotechnology Information non-redundant
    NS
    nonstructural protein
    Hsp
    heat shock protein
    hnRNP
    heterogeneous nuclear ribonucleoprotein
    eEF
    eukaryotic translation elongation factor
    eIF
    eukaryotic translation initiation factor

    • Received December 10, 2008.
    • Accepted April 21, 2009.
  • © 2009 The American Society for Biochemistry and Molecular Biology

REFERENCES

  1. 1.↵
    1. Schlesinger S.,
    2. Schlesinger M. J.
    1. Monath T. P.
    ( 1986) Pathobiology of the flaviviruses, in The Togaviridae and Flaviviridae ( Schlesinger S., Schlesinger M. J. eds) pp. 375– 453, Plenum Press New York
  2. 2.↵
    1. Campbell G. L.,
    2. Marfin A. A.,
    3. Lanciotti R. S.,
    4. Gubler D. J.
    ( 2002) West Nile virus. Lancet Infect. Dis. 2, 519– 529
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Granwehr B. P.,
    2. Lillibridge K. M.,
    3. Higgs S.,
    4. Mason P. W.,
    5. Aronson J. F.,
    6. Campbell G. A.,
    7. Barrett A. D.
    ( 2004) West Nile virus: where are we now? Lancet Infect. Dis. 4, 547– 556
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Lanciotti R. S.,
    2. Ebel G. D.,
    3. Deubel V.,
    4. Kerst A. J.,
    5. Murri S.,
    6. Meyer R.,
    7. Bowen M.,
    8. McKinney N.,
    9. Morrill W. E.,
    10. Crabtree M. B.,
    11. Kramer L. D.,
    12. Roehrig J. T.
    ( 2002) Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298, 96– 105
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Netherton C.,
    2. Moffat K.,
    3. Brooks E.,
    4. Wileman T.
    ( 2007) A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication. Adv. Virus Res. 70, 101– 182
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Prikhod'ko E. A.,
    2. Prikhod'ko G. G.,
    3. Siegel R. M.,
    4. Thompson P.,
    5. Major M. E.,
    6. Cohen J. I.
    ( 2004) The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 329, 53– 67
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Prikhod'ko G. G.,
    2. Prikhod'ko E. A.,
    3. Cohen J. I.,
    4. Pletnev A. G.
    ( 2001) Infection with Langat Flavivirus or expression of the envelope protein induces apoptotic cell death. Virology 286, 328– 335
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Prikhod'ko G. G.,
    2. Prikhod'ko E. A.,
    3. Pletnev A. G.,
    4. Cohen J. I.
    ( 2002) Langat flavivirus protease NS3 binds caspase-8 and induces apoptosis. J. Virol. 76, 5701– 5710
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ramanathan M. P.,
    2. Chambers J. A.,
    3. Pankhong P.,
    4. Chattergoon M.,
    5. Attatippaholkun W.,
    6. Dang K.,
    7. Shah N.,
    8. Weiner D. B.
    ( 2006) Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology 345, 56– 72
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Shafee N.,
    2. AbuBakar S.
    ( 2003) Dengue virus type 2 NS3 protease and NS2B-NS3 protease precursor induce apoptosis. J. Gen. Virol. 84, 2191– 2195
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Su H. L.,
    2. Liao C. L.,
    3. Lin Y. L.
    ( 2002) Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J. Virol. 76, 4162– 4171
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Chu J. J.,
    2. Ng M. L.
    ( 2003) The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J. Gen. Virol. 84, 3305– 3314
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Parquet M. C.,
    2. Kumatori A.,
    3. Hasebe F.,
    4. Mathenge E. G.,
    5. Morita K.
    ( 2002) St.Louis encephalitis virus induced pathology in cultured cells. Arch. Virol. 147, 1105– 1119
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Fields B. N.
    1. Monath T. P.,
    2. Heinz F. X.
    ( 1996) Flaviviruses, in Fields Virology ( Fields B. N. ed) 3rd Ed., pp. 961– 1034, Lippincott-Raven Publishers, Philadelphia
  15. 15.↵
    1. Peyrefitte C. N.,
    2. Pastorino B. A.,
    3. Bessaud M.,
    4. Gravier P.,
    5. Tock F.,
    6. Couissinier-Paris P.,
    7. Martial J.,
    8. Huc-Anais P.,
    9. Césaire R.,
    10. Grandadam M.,
    11. Tolou H. J.
    ( 2005) Dengue type 3 virus, Saint Martin, 2003–2004. Emerg. Infect. Dis. 11, 757– 761
    OpenUrlPubMed
  16. 16.↵
    1. Luria S. E.,
    2. Darnell J. E.,
    3. Baltimore D.,
    4. Campbell A.
    ( 1978) Titration of viruses, in General Virology, 3rd Ed, pp. 21– 32, Wiley, New York
  17. 17.↵
    1. Kleczkowski A.
    ( 1968) “Mathematical models” for infectivity dilution curves of plant viruses. Virology 34, 186– 187
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Pastorino B.,
    2. Bessaud M.,
    3. Grandadam M.,
    4. Murri S.,
    5. Tolou H. J.,
    6. Peyrefitte C. N.
    ( 2005) Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses. J. Virol. Methods 124, 65– 71
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Lanciotti R. S.,
    2. Kerst A. J.
    ( 2001) Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St.Louis encephalitis viruses. J. Clin. Microbiol. 39, 4506– 4513
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Marianneau P.,
    2. Mégret F.,
    3. Olivier R.,
    4. Morens D. M.,
    5. Deubel V.
    ( 1996) Dengue 1 virus binding to human hepatoma HepG2 and simian Vero cell surfaces differs. J. Gen. Virol. 77, 2547– 2554
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Laemmli U. K.
    ( 1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680– 685
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Towbin H.,
    2. Staehelin T.,
    3. Gordon J.
    ( 1992) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 24, 145– 149
    OpenUrlPubMed
  23. 23.↵
    1. Ekkapongpisit M.,
    2. Wannatung T.,
    3. Susantad T.,
    4. Triwitayakorn K.,
    5. Smith D. R.
    ( 2007) cDNA-AFLP analysis of differential gene expression in human hepatoma cells (HepG2) upon dengue virus infection. J. Med. Virol. 79, 552– 561
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Koh W. L.,
    2. Ng M. L.
    ( 2005) Molecular mechanisms of West Nile virus pathogenesis in brain cell. Emerg. Infect. Dis. 11, 629– 632
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Liew K. J.,
    2. Chow V. T.
    ( 2004) Differential display RT-PCR analysis of ECV304 endothelial-like cells infected with dengue virus type 2 reveals messenger RNA expression profiles of multiple human genes involved in known and novel roles. J. Med. Virol. 72, 597– 609
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Liew K. J.,
    2. Chow V. T.
    ( 2006) Microarray and real-time RT-PCR analyses of a novel set of differentially expressed human genes in ECV304 endothelial-like cells infected with dengue virus type 2. J. Virol. Methods 131, 47– 57
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Venter M.,
    2. Myers T. G.,
    3. Wilson M. A.,
    4. Kindt T. J.,
    5. Paweska J. T.,
    6. Burt F. J.,
    7. Leman P. A.,
    8. Swanepoel R.
    ( 2005) Gene expression in mice infected with West Nile virus strains of different neurovirulence. Virology 342, 119– 140
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Warke R. V.,
    2. Xhaja K.,
    3. Martin K. J.,
    4. Fournier M. F.,
    5. Shaw S. K.,
    6. Brizuela N.,
    7. de Bosch N.,
    8. Lapointe D.,
    9. Ennis F. A.,
    10. Rothman A. L.,
    11. Bosch I.
    ( 2003) Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J. Virol. 77, 11822– 11832
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Gygi S. P.,
    2. Rochon Y.,
    3. Franza B. R.,
    4. Aebersold R.
    ( 1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720– 1730
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Tian Q.,
    2. Stepaniants S. B.,
    3. Mao M.,
    4. Weng L.,
    5. Feetham M. C.,
    6. Doyle M. J.,
    7. Yi E. C.,
    8. Dai H.,
    9. Thorsson V.,
    10. Eng J.,
    11. Goodlett D.,
    12. Berger J. P.,
    13. Gunter B.,
    14. Linseley P. S.,
    15. Stoughton R. B.,
    16. Aebersold R.,
    17. Collins S. J.,
    18. Hanlon W. A.,
    19. Hood L. E.
    ( 2004) Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics 3, 960– 969
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Dhingra V.,
    2. Li Q.,
    3. Allison A. B.,
    4. Stallknecht D. E.,
    5. Fu Z. F.
    ( 2005) Proteomic profiling and neurodegeneration in West-Nile-virus-infected neurons. J. Biomed. Biotechnol. 2005, 271– 279
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Pattanakitsakul S. N.,
    2. Rungrojcharoenkit K.,
    3. Kanlaya R.,
    4. Sinchaikul S.,
    5. Noisakran S.,
    6. Chen S. T.,
    7. Malasit P.,
    8. Thongboonkerd V.
    ( 2007) Proteomic analysis of host responses in HepG2 cells during dengue virus infection. J. Proteome Res. 6, 4592– 4600
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Radtke K.,
    2. Döhner K.,
    3. Sodeik B.
    ( 2006) Viral interactions with the cytoskeleton: a hitchhiker's guide to the cell. Cell. Microbiol. 8, 387– 400
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Greber U. F.,
    2. Way M.
    ( 2006) A superhighway to virus infection. Cell 124, 741– 754
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Chu J. J.,
    2. Ng M. L.
    ( 2004) Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J. Virol. 78, 10543– 10555
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Chu J. J.,
    2. Choo B. G.,
    3. Lee J. W.,
    4. Ng M. L.
    ( 2003) Actin filaments participate in West Nile (Sarafend) virus maturation process. J. Med. Virol. 71, 463– 472
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Chiou C. T.,
    2. Hu C. C.,
    3. Chen P. H.,
    4. Liao C. L.,
    5. Lin Y. L.,
    6. Wang J. J.
    ( 2003) Association of Japanese encephalitis virus NS3 protein with microtubules and tumour susceptibility gene 101 (TSG101) protein. J. Gen. Virol. 84, 2795– 2805
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Manna T.,
    2. Sarkar T.,
    3. Poddar A.,
    4. Roychowdhury M.,
    5. Das K. P.,
    6. Bhattacharyya B.
    ( 2001) Chaperone-like activity of tubulin. binding and reactivation of unfolded substrate enzymes. J. Biol. Chem. 276, 39742– 39747
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Franke W. W.,
    2. Schmid E.,
    3. Winter S.,
    4. Osborn M.,
    5. Weber K.
    ( 1979) Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates. Exp. Cell Res. 123, 25– 46
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Rosevear E. R.,
    2. McReynolds M.,
    3. Goldman R. D.
    ( 1990) Dynamic properties of intermediate filaments: disassembly and reassembly during mitosis in baby hamster kidney cells. Cell Motil. Cytoskeleton 17, 150– 166
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Yoon M.,
    2. Moir R. D.,
    3. Prahlad V.,
    4. Goldman R. D.
    ( 1998) Motile properties of vimentin intermediate filament networks in living cells. J. Cell Biol. 143, 147– 157
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Stefanovic S.,
    2. Windsor M.,
    3. Nagata K. I.,
    4. Inagaki M.,
    5. Wileman T.
    ( 2005) Vimentin rearrangement during African swine fever virus infection involves retrograde transport along microtubules and phosphorylation of vimentin by calcium calmodulin kinase II. J. Virol. 79, 11766– 11775
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Tanaka M.,
    2. Kim Y. M.,
    3. Lee G.,
    4. Junn E.,
    5. Iwatsubo T.,
    6. Mouradian M. M.
    ( 2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625– 4631
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Sodeik B.
    ( 2002) Unchain my heart, baby let me go: the entry and intracellular transport of HIV. J. Cell Biol. 159, 393– 395
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Höner B.,
    2. Shoeman R. L.,
    3. Traub P.
    ( 1991) Human immunodeficiency virus type 1 protease microinjected into cultured human skin fibroblasts cleaves vimentin and affects cytoskeletal and nuclear architecture. J. Cell Sci. 100, 799– 807
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Shoeman R. L.,
    2. Höner B.,
    3. Stoller T. J.,
    4. Kesselmeier C.,
    5. Miedel M. C.,
    6. Traub P.,
    7. Graves M. C.
    ( 1990) Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. U.S.A. 87, 6336– 6340
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Byun Y.,
    2. Chen F.,
    3. Chang R.,
    4. Trivedi M.,
    5. Green K. J.,
    6. Cryns V. L.
    ( 2001) Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ. 8, 443– 450
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Ivaska J.,
    2. Pallari H. M.,
    3. Nevo J.,
    4. Eriksson J. E.
    ( 2007) Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 313, 2050– 2062
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Catteau A.,
    2. Courageot M. P.,
    3. Desprès P.
    ( 2004) Flaviviruses and apoptosis regulation. Prog. Mol. Subcell. Biol. 36, 171– 189
    OpenUrlPubMed
  50. 50.↵
    1. Morimoto R. I.,
    2. Tissieres A.,
    3. Georgopoulos C.
    1. Morimoto R. I.,
    2. Tissieres A.,
    3. Georgopoulos C.
    ( 1994) Progress and perspectives on the biology of heat shock proteins and molecular chaperones, in The Biology of Heat Shock Proteins and Molecular Chaperones ( Morimoto R. I., Tissieres A., Georgopoulos C. eds) pp. 1– 30, Cold Spring Harbor Press, Cold Spring Harbor, NY
  51. 51.↵
    1. Baroni A.,
    2. Paoletti I.,
    3. Ruocco E.,
    4. Ayala F.,
    5. Corrado F.,
    6. Wolf R.,
    7. Tufano M. A.,
    8. Donnarumma G.
    ( 2007) Antiviral effects of quinine sulfate on HSV-1 HaCat cells infected: analysis of the molecular mechanisms involved. J. Dermatol. Sci. 47, 253– 255
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Endo S.,
    2. Hiramatsu N.,
    3. Hayakawa K.,
    4. Okamura M.,
    5. Kasai A.,
    6. Tagawa Y.,
    7. Sawada N.,
    8. Yao J.,
    9. Kitamura M.
    ( 2007) Geranylgeranylacetone, an inducer of the 70-kDa heat shock protein (HSP70), elicits unfolded protein response and coordinates cellular fate independently of HSP70. Mol. Pharmacol. 72, 1337– 1348
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Oh W. K.,
    2. Song J.
    ( 2006) Hsp70 functions as a negative regulator of West Nile virus capsid protein through direct interaction. Biochem. Biophys. Res. Commun. 347, 994– 1000
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Jäättelä M.,
    2. Wissing D.,
    3. Kokholm K.,
    4. Kallunki T.,
    5. Egeblad M.
    ( 1998) Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 17, 6124– 6134
    OpenUrlAbstract
  55. 55.↵
    1. Neckers L.
    ( 2002) Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis. 15, 53– 60
    OpenUrlPubMed
  56. 56.↵
    1. Panaretou B.,
    2. Prodromou C.,
    3. Roe S. M.,
    4. O'Brien R.,
    5. Ladbury J. E.,
    6. Piper P. W.,
    7. Pearl L. H.
    ( 1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17, 4829– 4836
    OpenUrlAbstract
  57. 57.↵
    1. Agashe V. R.,
    2. Hartl F. U.
    ( 2000) Roles of molecular chaperones in cytoplasmic protein folding. Semin. Cell Dev. Biol. 11, 15– 25
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Pratt W. B.,
    2. Toft D. O.
    ( 2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228, 111– 133
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Hung J. J.,
    2. Chung C. S.,
    3. Chang W.
    ( 2002) Molecular chaperone Hsp90 is important for vaccinia virus growth in cells. J. Virol. 76, 1379– 1390
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Maggioni C.,
    2. Braakman I.
    ( 2005) Synthesis and quality control of viral membrane proteins. Curr. Top. Microbiol. Immunol. 285, 175– 198
    OpenUrlPubMed
  61. 61.↵
    1. Mayer M. P.
    ( 2005) Recruitment of Hsp70 chaperones: a crucial part of viral survival strategies. Rev. Physiol. Biochem. Pharmacol. 153, 1– 46
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Kampmueller K. M.,
    2. Miller D. J.
    ( 2005) The cellular chaperone heat shock protein 90 facilitates Flock House virus RNA replication in Drosophila cells. J. Virol. 79, 6827– 6837
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Momose F.,
    2. Naito T.,
    3. Yano K.,
    4. Sugimoto S.,
    5. Morikawa Y.,
    6. Nagata K.
    ( 2002) Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J. Biol. Chem. 277, 45306– 45314
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Nakagawa S.,
    2. Umehara T.,
    3. Matsuda C.,
    4. Kuge S.,
    5. Sudoh M.,
    6. Kohara M.
    ( 2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun. 353, 882– 888
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Okamoto T.,
    2. Nishimura Y.,
    3. Ichimura T.,
    4. Suzuki K.,
    5. Miyamura T.,
    6. Suzuki T.,
    7. Moriishi K.,
    8. Matsuura Y.
    ( 2006) Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 25, 5015– 5025
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Connor J. H.,
    2. McKenzie M. O.,
    3. Parks G. D.,
    4. Lyles D. S.
    ( 2007) Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362, 109– 119
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Geller R.,
    2. Vignuzzi M.,
    3. Andino R.,
    4. Frydman J.
    ( 2007) Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21, 195– 205
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Solit D. B.,
    2. Chiosis G.
    ( 2008) Development and application of Hsp90 inhibitors. Drug Discov. Today 13, 38– 43
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Li H. P.,
    2. Huang P.,
    3. Park S.,
    4. Lai M. M.
    ( 1999) Polypyrimidine tract-binding protein binds to the leader RNA of mouse hepatitis virus and serves as a regulator of viral transcription. J. Virol. 73, 772– 777
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Piñol-Roma S.
    ( 1997) HnRNP proteins and the nuclear export of mRNA. Semin. Cell Dev. Biol. 8, 57– 63
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Paranjape S. M.,
    2. Harris E.
    ( 2007) Y box-binding protein-1 binds to the dengue virus 3′-untranslated region and mediates antiviral effects. J. Biol. Chem. 282, 30497– 30508
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Noisakran S.,
    2. Sengsai S.,
    3. Thongboonkerd V.,
    4. Kanlaya R.,
    5. Sinchaikul S.,
    6. Chen S. T.,
    7. Puttikhunt C.,
    8. Kasinrerk W.,
    9. Limjindaporn T.,
    10. Wongwiwat W.,
    11. Malasit P.,
    12. Yenchitsomanus P. T.
    ( 2008) Identification of human hnRNP C1/C2 as a dengue virus NS1-interacting protein. Biochem. Biophys. Res. Commun. 372, 67– 72
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Zhang B.,
    2. Seitz S.,
    3. Kusov Y.,
    4. Zell R.,
    5. Gauss-Müller V.
    ( 2007) RNA interaction and cleavage of poly(C)-binding protein 2 by hepatitis A virus protease. Biochem. Biophys. Res. Commun. 364, 725– 730
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Bugler B.,
    2. Caizergues-Ferrer M.,
    3. Bouche G.,
    4. Bourbon H.,
    5. Amalric F.
    ( 1982) Detection and localization of a class of proteins immunologically related to a 100-kDa nucleolar protein. Eur. J. Biochem. 128, 475– 480
    OpenUrlPubMed
  75. 75.↵
    1. Callé A.,
    2. Ugrinova I.,
    3. Epstein A. L.,
    4. Bouvet P.,
    5. Diaz J. J.,
    6. Greco A.
    ( 2008) Nucleolin is required for an efficient herpes simplex virus type 1 infection. J. Virol. 82, 4762– 4773
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Hirano M.,
    2. Kaneko S.,
    3. Yamashita T.,
    4. Luo H.,
    5. Qin W.,
    6. Shirota Y.,
    7. Nomura T.,
    8. Kobayashi K.,
    9. Murakami S.
    ( 2003) Direct interaction between nucleolin and hepatitis C virus NS5B. J. Biol. Chem. 278, 5109– 5115
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Kushner D. B.,
    2. Lindenbach B. D.,
    3. Grdzelishvili V. Z.,
    4. Noueiry A. O.,
    5. Paul S. M.,
    6. Ahlquist P.
    ( 2003) Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc. Natl. Acad. Sci. U.S.A. 100, 15764– 15769
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Emara M. M.,
    2. Brinton M. A.
    ( 2007) Interaction of TIA-1/TIAR with West Nile and dengue virus products in infected cells interferes with stress granule formation and processing body assembly. Proc. Natl. Acad. Sci. U.S.A. 104, 9041– 9046
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Davis W. G.,
    2. Blackwell J. L.,
    3. Shi P. Y.,
    4. Brinton M. A.
    ( 2007) Interaction between the cellular protein eEF1A and the 3′-terminal stem-loop of West Nile virus genomic RNA facilitates viral minus-strand RNA synthesis. J. Virol. 81, 10172– 10187
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Chaudhuri J.,
    2. Chowdhury D.,
    3. Maitra U.
    ( 1999) Distinct functions of eukaryotic translation initiation factors eIF1A and eIF3 in the formation of the 40 S ribosomal preinitiation complex. J. Biol. Chem. 274, 17975– 17980
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Xiao H.,
    2. Xu L. H.,
    3. Yamada Y.,
    4. Liu D. X.
    (2008) Coronavirus spike protein inhibits host cell translation by interaction with eIF3f. PLoS ONE 3:e1494.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Bushell M.,
    2. Sarnow P.
    ( 2002) Hijacking the translation apparatus by RNA viruses. J. Cell Biol. 158, 395– 399
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Lloyd R. E.
    ( 2006) Translational control by viral proteinases. Virus Res. 119, 76– 88
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Yu S. W.,
    2. Wang H.,
    3. Poitras M. F.,
    4. Coombs C.,
    5. Bowers W. J.,
    6. Federoff H. J.,
    7. Poirier G. G.,
    8. Dawson T. M.,
    9. Dawson V. L.
    ( 2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297, 259– 263
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Bando Y.,
    2. Katayama T.,
    3. Aleshin A. N.,
    4. Manabe T.,
    5. Tohyama M.
    ( 2004) GRP94 reduces cell death in SH-SY5Y cells perturbated calcium homeostasis. Apoptosis 9, 501– 508
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Lu Y.,
    2. You F.,
    3. Vlahov I.,
    4. Westrick E.,
    5. Fan M.,
    6. Low P. S.,
    7. Leamon C. P.
    ( 2007) Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential. Mol. Pharm. 4, 695– 706
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Liao C. L.,
    2. Lin Y. L.,
    3. Wang J. J.,
    4. Huang Y. L.,
    5. Yeh C. T.,
    6. Ma S. H.,
    7. Chen L. K.
    ( 1997) Effect of enforced expression of human bcl-2 on Japanese encephalitis virus-induced apoptosis in cultured cells. J.Virol. 71 5963– 5971
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Molecular & Cellular Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Identification of Cellular Proteome Modifications in Response to West Nile Virus Infection
(Your Name) has sent you a message from Molecular & Cellular Proteomics
(Your Name) thought you would like to see the Molecular & Cellular Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Identification of Cellular Proteome Modifications in Response to West Nile Virus Infection
Boris Pastorino, Elodie Boucomont-Chapeaublanc, Christophe N. Peyrefitte, Maya Belghazi, Thierry Fusaï, Christophe Rogier, Hugues J. Tolou, Lionel Almeras
Molecular & Cellular Proteomics July 1, 2009, First published on April 24, 2009, 8 (7) 1623-1637; DOI: 10.1074/mcp.M800565-MCP200

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Request Permissions

Share
Identification of Cellular Proteome Modifications in Response to West Nile Virus Infection
Boris Pastorino, Elodie Boucomont-Chapeaublanc, Christophe N. Peyrefitte, Maya Belghazi, Thierry Fusaï, Christophe Rogier, Hugues J. Tolou, Lionel Almeras
Molecular & Cellular Proteomics July 1, 2009, First published on April 24, 2009, 8 (7) 1623-1637; DOI: 10.1074/mcp.M800565-MCP200
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

In this issue

Molecular & Cellular Proteomics: 8 (7)
Molecular & Cellular Proteomics
Vol. 8, Issue 7
1 Jul 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)

View this article with LENS

Jump to section

  • Article
    • Abstract
    • EXPERIMENTAL PROCEDURES
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

  • Follow MCP on Twitter
  • RSS feeds
  • Email

Articles

  • Current Issue
  • Papers in Press
  • Archive

For Authors

  • Submit a Manuscript
  • Info for Authors

Guidelines

  • Proteomic Identification
  • Clinical Proteomics
  • Glycomic Identification
  • Targeted Proteomics
  • Frequently Asked Questions

About MCP

  • About the Journal
  • Permissions and Licensing
  • Advertisers
  • Subscribers

ASBMB Publications

  • Molecular & Cellular Proteomics
  • Journal of Biological Chemistry
  • Journal of Lipid Research
  • ASBMB Today

© 2019 American Society for Biochemistry and Molecular Biology | Privacy Policy

MCP Print ISSN 1535-9476 Online ISSN 1535-9484

Powered by HighWire